Related Experiment Video
Updated: Jun 5, 2026
08:40
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
Natalizumab in pediatric multiple sclerosis patients
E Ann Yeh1, Bianca Weinstock-Guttman
1Pediatric Multiple Sclerosis and Demyelinating Disorders Center of the Jacobs Neurological Institute, Women and Children's Hospital of Buffalo, and Department of Neurology, State University of New York, Buffalo, NY, USA.
Therapeutic Advances in Neurological Disorders
|December 24, 2010
Summary
Pediatric multiple sclerosis (MS) is rare, and some children develop treatment-resistant disease. This review examines natalizumab use in pediatric MS, considering its risks and potential outcomes.
Area of Science:
- Neurology
- Pediatrics
- Immunology
Background:
- Pediatric multiple sclerosis (MS) accounts for 2-5% of all MS cases.
- First-line therapies like interferons and glatiramer acetate are generally well-tolerated but may be ineffective for some children.
- A subset of pediatric MS cases exhibits resistance to standard disease-modifying therapies (DMTs).
Purpose of the Study:
- To review current clinical experience with natalizumab in pediatric patients with multiple sclerosis.
- To evaluate the safety and efficacy of natalizumab in this specific population.
- To discuss the potential risks, including progressive multifocal leukoencephalopathy (PML), and long-term outcomes associated with natalizumab use in children.
Main Methods:
- Review of published case reports and clinical studies on natalizumab use in pediatric MS.
- Analysis of treatment outcomes, adverse events, and disease activity in pediatric patients.
- Assessment of the risk-benefit profile of natalizumab in comparison to other available therapies.
Main Results:
- Natalizumab has demonstrated potential for inducing disease remission in adults with highly active MS.
- Published reports suggest natalizumab may be effective in pediatric MS patients with treatment-resistant or highly active disease.
- While generally well-tolerated in adults, natalizumab carries a 1:1000 risk of progressive multifocal leukoencephalopathy (PML).
Conclusions:
- Natalizumab represents a therapeutic option for pediatric MS patients with highly active or treatment-resistant disease.
- Careful consideration of the risks, particularly PML, is essential when initiating natalizumab in children.
- Further research is needed to fully elucidate the long-term safety and efficacy of natalizumab in the pediatric MS population.
Related Concept Videos
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...